NZ581835A - Monoclonal anti beta amyloid antibody - Google Patents

Monoclonal anti beta amyloid antibody

Info

Publication number
NZ581835A
NZ581835A NZ581835A NZ58183508A NZ581835A NZ 581835 A NZ581835 A NZ 581835A NZ 581835 A NZ581835 A NZ 581835A NZ 58183508 A NZ58183508 A NZ 58183508A NZ 581835 A NZ581835 A NZ 581835A
Authority
NZ
New Zealand
Prior art keywords
seq
amino acid
nos
antibody
beta amyloid
Prior art date
Application number
NZ581835A
Other languages
English (en)
Inventor
Andrea Pfeifer
Maria Pihlgren
Andreas Muhs
Ryan Watts
Original Assignee
Ac Immune Sa
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ581835(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa, Genentech Inc filed Critical Ac Immune Sa
Priority to NZ601843A priority Critical patent/NZ601843A/en
Publication of NZ581835A publication Critical patent/NZ581835A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
NZ581835A 2007-06-12 2008-06-12 Monoclonal anti beta amyloid antibody NZ581835A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ601843A NZ601843A (en) 2007-06-12 2008-06-12 Monoclonal anti beta amyloid antibody

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94354107P 2007-06-12 2007-06-12
US94354307P 2007-06-12 2007-06-12
US94379007P 2007-06-13 2007-06-13
PCT/US2008/007317 WO2008156621A1 (en) 2007-06-12 2008-06-12 Monoclonal anti beta amyloid antibody

Publications (1)

Publication Number Publication Date
NZ581835A true NZ581835A (en) 2012-09-28

Family

ID=39790376

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ581835A NZ581835A (en) 2007-06-12 2008-06-12 Monoclonal anti beta amyloid antibody
NZ601843A NZ601843A (en) 2007-06-12 2008-06-12 Monoclonal anti beta amyloid antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601843A NZ601843A (en) 2007-06-12 2008-06-12 Monoclonal anti beta amyloid antibody

Country Status (18)

Country Link
EP (2) EP2527366B1 (https=)
JP (2) JP5436414B2 (https=)
KR (2) KR101600095B1 (https=)
CN (1) CN101802007B (https=)
AR (1) AR066987A1 (https=)
AU (1) AU2008267037B2 (https=)
BR (1) BRPI0812484A2 (https=)
CA (1) CA2690434C (https=)
CL (3) CL2008001742A1 (https=)
ES (1) ES2548102T3 (https=)
IL (1) IL202563A (https=)
MX (1) MX2009013503A (https=)
NZ (2) NZ581835A (https=)
PE (2) PE20131141A1 (https=)
RU (1) RU2571856C2 (https=)
TW (2) TWI516500B (https=)
WO (1) WO2008156621A1 (https=)
ZA (1) ZA201000049B (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2527366B1 (en) * 2007-06-12 2017-08-16 AC Immune S.A. Monoclonal anti beta amyloid antibody
RS53174B (sr) * 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
AR084020A1 (es) 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
WO2012111842A1 (ja) 2011-02-18 2012-08-23 国立大学法人東京農工大学 アミロイドタンパク質オリゴマー結合アプタマー
CN102921007B (zh) * 2011-08-09 2014-12-10 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
KR102129220B1 (ko) * 2011-09-23 2020-07-02 에이씨 이뮨 에스.에이. 백신 요법
AU2013266611B2 (en) 2012-05-21 2016-08-11 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
WO2014189973A2 (en) 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
CN109415431A (zh) * 2016-04-20 2019-03-01 爱兰细胞技术公司 与k180二甲基化h1.0蛋白相关的组合物和方法
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN112912732A (zh) * 2018-08-03 2021-06-04 香港大学 用于淀粉样蛋白原纤维、淀粉样蛋白斑块、rna和核仁的检测和成像的组合物和方法
KR101977410B1 (ko) * 2018-08-22 2019-05-10 주식회사 피플바이오 당뇨병에 대한 신규 바이오마커 및 그의 용도
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN111518205B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518206B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP3757125A1 (en) * 2019-06-28 2020-12-30 BioArctic AB Antibody directed against the apoe amino-terminal fragment of 12 kda
CN110317814A (zh) * 2019-07-19 2019-10-11 莫丁丁 β-淀粉样蛋白环状核糖核酸、多肽及其应用
MX2022002873A (es) * 2019-09-10 2022-03-25 Ac Immune Sa Nuevas moleculas para diagnostico.
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
CN110687035A (zh) * 2019-10-10 2020-01-14 沈阳万类生物科技有限公司 Annexin V-Light 650凋亡检测试剂盒
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
CN113308439B (zh) * 2020-11-06 2023-05-05 华中科技大学 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用
CN113057963B (zh) * 2021-03-31 2022-05-20 华中科技大学 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
KR102565471B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물
KR102565470B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN119390832A (zh) * 2024-10-12 2025-02-07 中国科学技术大学 一种兔源Aβ 1-40单克隆抗体、制备方法及应用
CN120098147B (zh) * 2025-05-07 2025-07-15 中山大学 一种纳米自组装抗Aβ抗体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
ZA938243B (en) * 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
CA2127476C (en) 1994-07-06 1999-12-07 Daniel G. Pomerleau Logging or measurement while tripping
WO1996013590A2 (en) 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
DE852011T1 (de) * 1995-09-14 2001-10-11 Scripps Res Inst La Jolla Für natives prp-sc spezifische antikörper
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
DE60226036T9 (de) * 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
WO2003039467A2 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid.
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004065569A2 (en) * 2003-01-23 2004-08-05 The Regents Of The University Of California Multi-functional antibodies
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
BRPI0513959A (pt) * 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
NZ562434A (en) * 2005-05-05 2010-04-30 Merck & Co Inc Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2527366B1 (en) * 2007-06-12 2017-08-16 AC Immune S.A. Monoclonal anti beta amyloid antibody

Also Published As

Publication number Publication date
PE20090831A1 (es) 2009-07-10
TW201441256A (zh) 2014-11-01
EP2170953B1 (en) 2015-07-15
JP2010530227A (ja) 2010-09-09
KR20100027216A (ko) 2010-03-10
CL2012001817A1 (es) 2012-12-14
PE20131141A1 (es) 2013-10-14
WO2008156621A1 (en) 2008-12-24
IL202563A0 (en) 2011-08-01
IL202563A (en) 2016-05-31
KR20160017126A (ko) 2016-02-15
AR066987A1 (es) 2009-09-23
AU2008267037A1 (en) 2008-12-24
TWI516500B (zh) 2016-01-11
CN101802007B (zh) 2017-08-25
RU2010100354A (ru) 2011-07-20
EP2527366A1 (en) 2012-11-28
NZ601843A (en) 2014-01-31
TW200906852A (en) 2009-02-16
MX2009013503A (es) 2010-01-27
CA2690434A1 (en) 2008-12-24
ES2548102T3 (es) 2015-10-13
EP2527366B1 (en) 2017-08-16
ZA201000049B (en) 2018-11-28
CN101802007A (zh) 2010-08-11
JP2014087353A (ja) 2014-05-15
AU2008267037B2 (en) 2014-08-07
CL2012000631A1 (es) 2012-10-05
BRPI0812484A2 (pt) 2018-06-05
CA2690434C (en) 2018-05-22
CL2008001742A1 (es) 2008-11-21
RU2571856C2 (ru) 2015-12-20
TWI453217B (zh) 2014-09-21
EP2170953A1 (en) 2010-04-07
KR101600095B1 (ko) 2016-03-07
HK1140500A1 (en) 2010-10-15
JP5436414B2 (ja) 2014-03-05

Similar Documents

Publication Publication Date Title
NZ581835A (en) Monoclonal anti beta amyloid antibody
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
MX2025003227A (es) Anticuerpo anti-interleucina-17a, composicion farmaceutica y uso de los mismos
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201990570A1 (ru) Моноклональное антитело против pd1, его фармацевтическая композиция и их применение
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
NZ592542A (en) Toll-like receptor 3 antagonists
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ596295A (en) Anti-5T4 antibodies and uses thereof
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
NZ626269A (en) Anti-phf-tau antibodies and their uses
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
NZ599204A (en) High affinity human antibodies to human protease-activated receptor-2
WO2009004066A3 (en) Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
MY172718A (en) Humanized universal light chain mice
NZ598770A (en) Monoclonal antibodies
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
NZ594682A (en) Fully human antibodies specific to cadm1
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
NZ616761A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 JUN 2015 BY AJ PARK

Effective date: 20130305

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 161198, GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CALIFORNIA 94080, US; 1205253, AC IMMUNE S.A., EPFL INNOVATION PARK BUILDING B, CH-1015 LAUSANNE, CH

Effective date: 20150511

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2016 BY THOMSON REUTERS

Effective date: 20150514

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2017 BY THOMSON REUTERS

Effective date: 20160512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2018 BY THOMSON REUTERS

Effective date: 20170527

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2019 BY THOMSON REUTERS

Effective date: 20180509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2020 BY THOMSON REUTERS

Effective date: 20190516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2021 BY THOMSON REUTERS

Effective date: 20200517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2022 BY THOMSON REUTERS

Effective date: 20210505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2023 BY THOMSON REUTERS

Effective date: 20220502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2024 BY THOMSON REUTERS

Effective date: 20230501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250520